The Jackson Laboratory (JAX) has completed its acquisition of the New York Stem Cell Foundation (NYSCF), bringing together expertise in genetics, mouse models, and advanced stem cell and automation technologies. The integration aims to create a platform for early-stage biomedical research, supporting progress toward therapies for diseases such as Alzheimer’s, cancer, diabetes, Parkinson’s, and rare diseases.
This acquisition combines JAX’s experience in mouse genetics and preclinical modeling with NYSCF’s work in stem cell science, automation, and high-throughput discovery.
NYSCF has developed what they call The NYSCF Global Stem Cell Array®. It’s essentially a robotic platform that automates the reprogramming and differentiation of patient-derived cells, enabling large-scale, reproducible stem-cell research. Together, JAX’s genetic and in-vivo modeling capabilities and NYSCF’s automation and human-cell platforms could form a very comprehensive preclinical-to-clinical discovery pipeline in regenerative medicine.
The unified JAX–NYSCF organization will continue operating as a nonprofit. NYSCF will maintain its New York presence while JAX expands its research network across Maine, Connecticut, California, Florida, and Japan.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
